Moderate and chronic consumption of reduced-alcohol red wine alleviated pulmonary arterial hypertension (PAH) in a rat model. The study was published online in BMC Research Notes.
The study authors stated, “The daily treatment with moderate [reduced-alcohol red wine] in this PAH rat model reduced [right ventricular] hypertrophy and improved pulmonary artery flow.”
They found that chronic consumption of reduced-alcohol red wine restricted right ventricular hypertrophy induced by monocrotaline, as well as increased pulmonary artery acceleration time and decreased the concentration of conjugated dienes. The protective effect was associated with reduced lipid peroxidation.
Read more about PAH experimental therapies
Therefore, the study authors suggested that chronic moderate consumption of reduced-alcohol red wine or its components might add value as a new protective strategy to limit cardiovascular dysfunction in PAH.
In the study, Diaba-Nuhoho et al used a wine concentration that mimicked moderate intake for humans. Rats started consuming wine 7 days before a monocrotaline (80 mg/kg subcutaneous, 0.1 mL) injection, which was used to induce pulmonary hypertension. Wine consumption was continued until 28 days after the injection.
By that time, the study authors observed right ventricular hypertrophy, alteration of pulmonary artery flow, and increased concentrations of conjugated dienes and thiobarbituric acid reactive substances in monocrotaline-induced PAH rats, when compared to controls.
Diaba-Nuhoho P, Cour M, Hadebe N, Marais D, Lecour S, Blackhurst D. Chronic and moderate consumption of reduced-alcohol wine confers cardiac benefits in a rat model of pulmonary arterial hypertension. BMC Res Notes. 2021;14(1):324. doi:10.1186/s13104-021-05738-x